BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 2014;349:258-67. [PMID: 24570071 DOI: 10.1124/jpet.114.213256] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatol Res. 2016; Epub ahead of print. [PMID: 27670393 DOI: 10.1111/hepr.12822] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2021;25:467-78. [PMID: 33471240 DOI: 10.1007/s10157-020-02009-0] [Reference Citation Analysis]
3 Sagar PS, Zhang J, Luciuk M, Mannix C, Wong ATY, Rangan GK. Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. PLoS One 2019;14:e0209186. [PMID: 30601830 DOI: 10.1371/journal.pone.0209186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ortiz A, Sanchez-Niño MD, Izquierdo MC, Martin-Cleary C, Garcia-Bermejo L, Moreno JA, Ruiz-Ortega M, Draibe J, Cruzado JM, Garcia-Gonzalez MA, Lopez-Novoa JM, Soler MJ, Sanz AB; Red de Investigacion Renal (REDINREN) and Consorcio Madrileño para investigación del fracaso renal agudo (CIFRA). Translational value of animal models of kidney failure. Eur J Pharmacol 2015;759:205-20. [PMID: 25814248 DOI: 10.1016/j.ejphar.2015.03.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
5 Torres VE. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2019;34:30-4. [PMID: 30312438 DOI: 10.1093/ndt/gfy297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Nakatani S, Nishide K, Okuno S, Ishimura E, Kabata D, Morioka F, Machiba Y, Uedono H, Tsuda A, Shoji S, Inaba M, Mori K, Yamakawa T, Emoto M. Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease. Sci Rep 2021;11:10014. [PMID: 33976330 DOI: 10.1038/s41598-021-89480-1] [Reference Citation Analysis]
7 Molinari E, Sayer JA. Disease Modeling To Understand the Pathomechanisms of Human Genetic Kidney Disorders. Clin J Am Soc Nephrol 2020;15:855-72. [PMID: 32139361 DOI: 10.2215/CJN.08890719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sakai K, Yamazaki O, Ishizawa K, Tamura Y, Wang Q, Ueno M, Hayama Y, Fujigaki Y, Shibata S. Upregulation of renal Na-K-2Cl cotransporter 2 in obese diabetes mellitus via a vasopressin receptor 2-dependent pathway. Biochem Biophys Res Commun 2020;524:710-5. [PMID: 32035616 DOI: 10.1016/j.bbrc.2020.01.142] [Reference Citation Analysis]
9 Vasileva VY, Sultanova RF, Sudarikova AV, Ilatovskaya DV. Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases. Front Physiol 2021;12:693130. [PMID: 34566674 DOI: 10.3389/fphys.2021.693130] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 2018;13:1153-61. [PMID: 30026287 DOI: 10.2215/CJN.01520218] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
11 Sussman CR, Wang X, Chebib FT, Torres VE. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. Cell Signal 2020;72:109649. [PMID: 32335259 DOI: 10.1016/j.cellsig.2020.109649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
12 Erokwu BO, Anderson CE, Flask CA, Dell KM. Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model. Pediatr Res 2018;83:1067-74. [DOI: 10.1038/pr.2018.24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J 2021;35:e21874. [PMID: 34486176 DOI: 10.1096/fj.202100774R] [Reference Citation Analysis]
14 Duong Phu M, Bross S, Burkhalter MD, Philipp M. Limitations and opportunities in the pharmacotherapy of ciliopathies. Pharmacol Ther 2021;225:107841. [PMID: 33771583 DOI: 10.1016/j.pharmthera.2021.107841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ramos AM, Fernández-Fernández B, Pérez-Gómez MV, Carriazo Julio SM, Sanchez-Niño MD, Sanz A, Ruiz-Ortega M, Ortiz A. Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opin Drug Discov 2020;15:101-15. [PMID: 31736379 DOI: 10.1080/17460441.2020.1690450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol 2015;308:F261-6. [PMID: 25503729 DOI: 10.1152/ajprenal.00345.2014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
17 Blair HA, Keating GM. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs 2015;75:1797-806. [PMID: 26407729 DOI: 10.1007/s40265-015-0475-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
18 Blair HA. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs 2019;79:303-13. [DOI: 10.1007/s40265-019-1056-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
19 Zittema D, Versteeg IB, Gansevoort RT, van Goor H, de Heer E, Veraar KA, Peters DJ, Meijer E. Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 2016;44:194-203. [PMID: 27578560 DOI: 10.1159/000448693] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, Kersjes K, Li J, Gatto S, Takhar M, Lockton S, Pavlicek A, Kim M, Chu T, Soriano R, Davis S, Androsavich JR, Sarwary S, Owen T, Kaplan J, Liu K, Jang G, Neben S, Bentley P, Wright T, Patel V. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun 2019;10:4148. [PMID: 31515477 DOI: 10.1038/s41467-019-11918-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
21 Oey O, Rao P, Luciuk M, Mannix C, Rogers NM, Sagar P, Wong A, Rangan G. Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis. Exp Biol Med (Maywood) 2018;243:428-36. [PMID: 29436846 DOI: 10.1177/1535370218759313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthc Patient Saf 2017;9:93-104. [PMID: 29123425 DOI: 10.2147/DHPS.S142825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
23 Chebib FT, Torres VE. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 2018;13:1765-76. [PMID: 30049849 DOI: 10.2215/CJN.03960318] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
24 Aukema HM. Prostaglandins as potential targets for the treatment of polycystic kidney disease. Prostaglandins Leukot Essent Fatty Acids 2021;164:102220. [PMID: 33285393 DOI: 10.1016/j.plefa.2020.102220] [Reference Citation Analysis]
25 Kai H, Shinozaki Y, Nishikubo A, Watanabe M, Tawara T, Iwase M, Tsunoda R, Moriyama N, Usui T, Kawamura T, Nagai K, Hagiwara M, Saito C, Morito N, Usui J, Yamagata K. Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. CEN Case Rep 2016;5:87-90. [PMID: 28509176 DOI: 10.1007/s13730-015-0198-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Srivastava S, Molinari E, Raman S, Sayer JA. Many Genes-One Disease? Front Pediatr. 2017;5:287. [PMID: 29379777 DOI: 10.3389/fped.2017.00287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
27 Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol 2018;29:2458-70. [PMID: 30228150 DOI: 10.1681/ASN.2018060590] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
28 Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene 2020;39:1231-45. [PMID: 31616061 DOI: 10.1038/s41388-019-1059-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
29 Slaats GG, Lilien MR, Giles RH. Nephronophthisis: should we target cysts or fibrosis? Pediatr Nephrol 2016;31:545-54. [PMID: 26219413 DOI: 10.1007/s00467-015-3162-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
30 Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Pediatr Nephrol 2018;33:395-408. [PMID: 28455745 DOI: 10.1007/s00467-017-3672-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 2017;32:969-75. [PMID: 27190355 DOI: 10.1093/ndt/gfw060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
32 Monirujjaman M, Devassy JG, Yamaguchi T, Sidhu N, Kugita M, Gabbs M, Nagao S, Zhou J, Ravandi A, Aukema HM. Distinct oxylipin alterations in diverse models of cystic kidney diseases. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2017;1862:1562-74. [DOI: 10.1016/j.bbalip.2017.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]